-
[Latest] Global Women’s Health Rehabilitation Products Market Size Envisioned at USD 9.68 Billion by 2034, Increasing a CAGR of 6.6% | Healthcare Revolution
07 Aug 2025 17:52 GMT
… (U.S.), Accord Medical Products (U.S.), … 2030
Fabry Disease Treatment Market By Treatment (Substrate Reduction … Diagnostic Laboratories, Hospitals, Pharmaceutical & Biotechnology Companies, And Research … Growth Factors {Filgrastim And Lenograstim}, Cancer …
-
Study Highlights Filgrastim Savings Potential With Biosimilars
18 Jul 2025 16:14 GMT
… examined a single drug to treat neutropenia, filgrastim (Neupogen; Amgen), … patients over 6 chemotherapy trials.2 In the study … cost-effective method of treatment that simultaneously increases access … administration of the incorrect medication.
It takes proper …
-
FDA’s Published CRLs Deliver Insight Into the Drug Approval Process
16 Jul 2025 17:44 GMT
… drug developer perform an additional adequate, well-controlled, randomized clinical trial … ; filgrastim-ayow), a biosimilar referencing filgrastim ( … Pharmaceuticals receives FDA approval for Lymphir (denileukin diftitox-cxdl) immunotherapy for the treatment …
-
Bio-Thera Solutions Announces FDA Accepts Biologics License Application For BAT2506, A Proposed Biosimilar To Simponi®
16 Jul 2025 12:37 GMT
… S. Food and Drug Administration (FDA) has accepted … ).
About Intas Pharmaceuticals
Intas Pharmaceuticals is a pioneer … affordable treatment option, Intas' products like Neukine (filgrastim), … (EU-GMP) certified biotechnology plant located near Ahmedabad, …
-
Sunshine Biopharma’s Canadian subsidiary, Nora Pharma launches biosimilar drug, Niopeg
04 Jul 2025 10:53 GMT
… a pharmaceutical company offering and researching life-saving medicines in … to the reference biologic drug Neulasta (Pegfilgrastim). Like … colony-stimulating factor (filgrastim). It is indicated … small molecule for treatment of SARS Coronavirus infections …
-
Aurobindo Pharma shares in focus after European Commission nod for cancer drug Dazublys
03 Jul 2025 10:02 GMT
… April 2025 from the European Medicines Agency’s (EMA) … Committee for Medicinal Products for Human Use … reference drug Herceptin.
Dazublys is indicated for the treatment of … Dyrupeg (pegylated filgrastim) in April and Zefylti (filgrastim) in February. …
-
Global Chemotherapy-Induced Neutropenia Treatment Market To Reach $0.76 Billion By 2029 With A Growth Rate Of 5.3%
13 Jun 2025 15:33 GMT
… , and expanding oncology drug pipelines. Rising chemotherapy … , Novartis AG, Takeda Pharmaceutical Company Limited, Amgen Inc … treatment market. For example, Coherus BioSciences Inc. received FDA … Factor Therapy G-CSF: Filgrastim, Pegfilgrastim, Lenograstim
3 …
-
‘How was this missed for SO long?’ Woman, 32, reveals the signs of killer cancer doctors repeatedly ignored
30 Apr 2025 10:06 GMT
… to be repeatedly dismissed by doctors.
“I was turned away … the bone pain from the Filgrastim injections have been the hardest … body is responding to the treatment.
What is Hodgkin lymphoma?
…
For anyone facing pushback from doctors, Emma urged them to trust …
-
Human medicines European public assessment report (EPAR): Pelmeg, pegfilgrastim, Date of authorisation: 20/11/2018, Revision: 10, Status: Authorised
02 Apr 2025 23:01 GMT
… each cycle of chemotherapy (treatment with cancer medicines). Patients can inject themselves … package leaflet or contact your doctor or pharmacist.
How does Pelmeg … -colony-stimulating factor (G-CSF). Filgrastim works by encouraging the bone …
-
CuraTeQ Biologics received Marketing Authorization for Dyrupeg™, a pegylated filgrastim biosimilar
07 Apr 2025 13:40 GMT
… (EU) for Dyrupeg™, a pegylated filgrastim biosimilar, to CuraTeQ Biologics s … , the Committee for Medicinal Products (CHMP) of European Medicines Agency had adopted …